Brokerages Set Repligen Co. (NASDAQ:RGEN) PT at $188.38

Repligen Co. (NASDAQ:RGEN) has been given a consensus rating of “Moderate Buy” by the ten brokerages that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $188.38.

A number of equities research analysts recently weighed in on the company. Wells Fargo & Company assumed coverage on Repligen in a research report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 target price on the stock. Benchmark restated a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $190.00 target price on shares of Repligen in a research report on Wednesday, July 31st. Stephens reissued an “overweight” rating and issued a $170.00 price target on shares of Repligen in a report on Tuesday, July 30th. Finally, Guggenheim initiated coverage on shares of Repligen in a report on Tuesday, June 18th. They set a “neutral” rating for the company.

Repligen Stock Performance

Shares of NASDAQ RGEN opened at $139.99 on Monday. Repligen has a 12 month low of $110.45 and a 12 month high of $211.13. The company has a market cap of $7.84 billion, a P/E ratio of 559.98, a P/E/G ratio of 4.24 and a beta of 0.94. The business’s 50 day moving average is $145.43 and its two-hundred day moving average is $157.36. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33. The firm had revenue of $154.07 million during the quarter, compared to analysts’ expectations of $154.11 million. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The business’s quarterly revenue was down 3.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.53 EPS. On average, equities analysts expect that Repligen will post 1.45 EPS for the current year.

Insider Activity at Repligen

In other Repligen news, VP Ralf Kuriyel sold 4,465 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $165.67, for a total transaction of $739,716.55. Following the sale, the vice president now directly owns 19,261 shares of the company’s stock, valued at $3,190,969.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at $20,328,540.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Ralf Kuriyel sold 4,465 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the sale, the vice president now directly owns 19,261 shares in the company, valued at approximately $3,190,969.87. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Repligen

Large investors have recently modified their holdings of the stock. Evoke Wealth LLC bought a new position in Repligen in the 4th quarter worth approximately $1,955,000. Norden Group LLC raised its position in shares of Repligen by 1,711.6% during the first quarter. Norden Group LLC now owns 38,805 shares of the biotechnology company’s stock worth $7,137,000 after acquiring an additional 36,663 shares during the last quarter. Artemis Investment Management LLP lifted its stake in shares of Repligen by 33.8% during the first quarter. Artemis Investment Management LLP now owns 167,813 shares of the biotechnology company’s stock valued at $30,852,000 after acquiring an additional 42,380 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in Repligen by 30.2% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 28,883 shares of the biotechnology company’s stock valued at $5,312,000 after acquiring an additional 6,705 shares during the last quarter. Finally, Congress Asset Management Co. MA increased its position in Repligen by 14.6% in the first quarter. Congress Asset Management Co. MA now owns 88,013 shares of the biotechnology company’s stock worth $16,187,000 after purchasing an additional 11,213 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.